Phase II study of lonidamine in non-small cell lung cancer: final report.

Lonidamine (LND) is a new anti-cancer drug which interferes with the energy-yielding processes of tumour cells without affecting DNA replication. A total of 69 previously untreated patients with non-small cell lung cancer (NSCLC) entered this study. LND was given orally as a single agent at doses ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kokron, O., Maca, S., De Gregorio, M., Ciottoli, G. B.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971425/
https://www.ncbi.nlm.nih.gov/pubmed/2155644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971425/
https://www.ncbi.nlm.nih.gov/pubmed/2155644

Ejemplares similares